Literature DB >> 34151200

Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma.

Rachel L Mynott1, Craig T Wallington-Beddoe1,2,3,4.   

Abstract

Multiple myeloma remains an incurable malignancy of plasma cells. Novel therapies, notably proteasome inhibitors and immunomodulatory drugs, have improved the survival of multiple myeloma patients; however, patients either present with, or develop resistance to, these therapies. Resistance to traditional chemotherapeutic agents can be caused by cellular drug efflux via adenosine triphosphate (ATP)-binding cassette (ABC) transporters, but it is still not clear whether these transporters mediate resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma. Solute carrier (SLC) transporters also play a role in cancer drug resistance due to changes in cell homeostasis caused by their abnormal expression and changes in the solutes they transport. In this review, we evaluate resistance to novel therapies used to treat multiple myeloma, as mediated by drug and solute transporters.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID： 34151200      PMCID： PMC8204322          DOI： 10.1021/acsptsci.1c00074

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN： 2575-9108


  136 in total

1.  CD40 stimulation induces vincristine resistance via AKT activation and MRP1 expression in a human multiple myeloma cell line.

Authors:  Soo-Woong Lee; Hae-Yun Cho; Giyoun Na; Mi Ra Yoo; Su-Kil Seo; Dae Young Hur; Jin Han; Chae Kwan Lee; Inhak Choi
Journal:  Immunol Lett       Date:  2012-03-14       Impact factor: 3.685

2.  Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma.

Authors:  Takahiro Kobayashi; Masatomo Miura; Maiko Abumiya; Yumiko Akamine; Fumiko Ito; Naoto Takahashi
Journal:  Med Oncol       Date:  2019-05-14       Impact factor: 3.064

3.  Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma.

Authors:  H G Raaijmakers; M A Izquierdo; H M Lokhorst; C de Leeuw; J A Belien; A C Bloem; A W Dekker; R J Scheper; P Sonneveld
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

Review 4.  Cyclophosphamide and cancer: golden anniversary.

Authors:  Ashkan Emadi; Richard J Jones; Robert A Brodsky
Journal:  Nat Rev Clin Oncol       Date:  2009-09-29       Impact factor: 66.675

5.  A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study.

Authors:  W S Dalton; J J Crowley; S S Salmon; T M Grogan; L R Laufman; G R Weiss; J D Bonnet
Journal:  Cancer       Date:  1995-02-01       Impact factor: 6.860

6.  High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.

Authors:  Daniel Heintel; Alberto Rocci; Heinz Ludwig; Arnold Bolomsky; Simona Caltagirone; Martin Schreder; Sabine Pfeifer; Heinz Gisslinger; Niklas Zojer; Ulrich Jäger; Antonio Palumbo
Journal:  Br J Haematol       Date:  2013-04-09       Impact factor: 6.998

7.  Drug metabolism and clearance system in tumor cells of patients with multiple myeloma.

Authors:  Wafa Hassen; Alboukadel Kassambara; Thierry Reme; Surinder Sahota; Anja Seckinger; Laure Vincent; Guillaume Cartron; Jérôme Moreaux; Dirk Hose; Bernard Klein
Journal:  Oncotarget       Date:  2015-03-20

8.  Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.

Authors:  Ingrid Jakobsen Falk; Johan Lund; Henrik Gréen; Astrid Gruber; Evren Alici; Birgitta Lauri; Cecilie Blimark; Ulf-Henrik Mellqvist; Agneta Swedin; Karin Forsberg; Conny Carlsson; Mats Hardling; Lucia Ahlberg; Kourosh Lotfi; Hareth Nahi
Journal:  Cancer Chemother Pharmacol       Date:  2017-11-25       Impact factor: 3.333

Review 9.  Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update.

Authors:  Hanley N Abramson
Journal:  Int J Mol Sci       Date:  2018-12-07       Impact factor: 5.923

Review 10.  Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer.

Authors:  Pranavi Koppula; Yilei Zhang; Li Zhuang; Boyi Gan
Journal:  Cancer Commun (Lond)       Date:  2018-04-25
View more
  4 in total

Review 1.  Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets.

Authors:  Daniela N Petrusca; Kelvin P Lee; Deborah L Galson
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

2.  Synthesis and In Vitro Activity of Novel Melphalan Analogs in Hematological Malignancy Cells.

Authors:  Anastazja Poczta; Piotr Krzeczyński; Joanna Tobiasz; Aneta Rogalska; Arkadiusz Gajek; Agnieszka Marczak
Journal:  Int J Mol Sci       Date:  2022-02-03       Impact factor: 5.923

3.  Hypoxia-Immune-Related Gene SLC19A1 Serves as a Potential Biomarker for Prognosis in Multiple Myeloma.

Authors:  Wenjin Li; Peng Yuan; Weiqin Liu; Lichan Xiao; Chun Xu; Qiuyu Mo; Shujuan Xu; Yuchan He; Duanfeng Jiang; Xiaotao Wang
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

4.  Cancer drug resistance in multiple myeloma.

Authors:  Fatih M Uckun
Journal:  Cancer Drug Resist       Date:  2022-03-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.